CHRISTINA COUGHLIN was named chief medical officer of Immunocore Ltd.
Most recently, Coughlin was leading two early development programs at Novartis in checkpoint inhibition and PI3 kinase inhibition. She led the overall program early development teams, including preclinical pharmacology, toxicology, clinical pharmacology, clinical development, biomarker development and regulatory work.
Before that, she served as international project team leader at Morphotek Inc., where she led the early clinical development team responsible for monoclonal antibody development against novel targets.
